Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 1, 2005, Pages 313-319

  Grant, Marianne K O ^a   El Fakahany, Esam E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBACHOL; CELL SURFACE RECEPTOR; ISOPROTEIN; MUSCARINIC M5 RECEPTOR; PHOSPHATIDYLINOSITIDE; PILOCARPINE; XANOMELINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DENSITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; FEMALE; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CARBACHOL; CHO CELLS; CRICETINAE; INOSITOL PHOSPHATES; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; N-METHYLSCOPOLAMINE; PILOCARPINE; PYRIDINES; RECEPTOR, MUSCARINIC M5; THIADIAZOLES;

EID: 25644437115     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.090134     Document Type: Article

References (26)

1. Barlow RB, Scott NC, and Stephenson RP (1967) The affinity and efficacy of onium salts on the frog rectus abdominis. Br J Pharmacol 31:188-196.
2. Basile AS, Fedorova I, Zapata A, Liu X, Shippenberg T, Duttaroy A, Yamada M, and Wess J (2002) Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci USA 99:11452-11457.
3. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
4. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465-473.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, Calligaro DO, Whitesitt CA, DeLapp N, Shannon HE, et al. (1998) Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res 795:179-190.
7. Bymaster FP, Whitesitt CA, Shannon HE, DeLapp N, Ward JS, Calligaro DO, Shipley LA, Buelke-Sam JL, Bodick NC, Farde L, et al. (1997) Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 40:158-170.
8. Caulfield MP (1993) Muscarinic receptors-characterization, coupling and function. Pharmacol Ther 58:319-379.
9. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Christopoulos A, Parsons AM, and El-Fakahany EE (1999) Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor. J Pharmacol Exp Ther 289:1220-1228.
11. Christopoulos A, Pierce TL, Sorman JL, and El-Fakahany EE (1998) On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor. Mol Pharmacol 53:1120-1130.
12. Ehlert FJ (1985) The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol Pharmacol 28:410-421.
13. Fink-Jensen A, Fedorova I, Wortwein G, Woldbye DP, Rasmussen T, Thomsen M, Bolwig TG, Knitowski KM, McKinzie DL, Yamada M, et al. (2003) Role for M5 muscarinic acetylcholine receptors in cocaine addiction. J Neurosci Res 74:91-96.
14. Forster GL, Yeomans JS, Takeuchi J, and Blaha CD (2002) M5 muscarinic receptors are required for prolonged accumbal dopamine release after electrical stimulation of the pons in mice. J Neurosci 22:RC190.
15. Hulme EC, Birdsall NJ, and Buckley NJ (1990) Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol 30:633-673.
16. Jakubik J, Tucek S, and El-Fakahany EE (2002) Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor. J Pharmacol Exp Ther 301:1033-1041.
17. Jakubik J, Tucek S, and El-Fakahany EE (2004) Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to muscarinic M1 receptors. J Pharmacol Exp Ther 308:105-110.
18. Ladner CJ and Lee JM (1998) Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 57:719-731.
19. Medina A, Bodick N, Goldberger AL, Mahon MM, and Lipsitz LA (1997) Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Hypertension 29:828-834.
20. Motulsky HJ and Christopoulos A (2003) Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting. GraphPad Software Inc., San Diego, CA.
21. Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD, Ward JS, Wong DT, Olesen PH, Sheardown MJ, et al. (1994) Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther 269:271-281.
22. Ward JS, Merritt L, Calligaro DO, Bymaster FP, Shannon HE, Sawyer BD, Mitch CH, Deeter JB, Peters SC, Sheardown MJ, et al. (1995) Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles. J Med Chem 38:3469-3481.
23. Watson J, Brough S, Coldwell M, Gager T, Ho M, Hunter A, Jerman J, Middlemiss D, Riley G, and Brown A (1998) Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol 125:1413-1420.
24. Wess J (2004) Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 44:423-450.
25. Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, and Middlemiss DN (1999) Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br J Pharmacol 126:1620-1624.
26. Yamada M, Basile AS, Fedorova I, Zhang W, Duttaroy A, Cui Y, Lamping KG, Faraci FM, Deng CX, and Wess J (2003) Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. Life Sci 74:345-353.